Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors.

Jodon G, Fischer SM, Kessler ER.

Drugs Aging. 2018 May;35(5):409-421. doi: 10.1007/s40266-018-0540-8. Review.

2.

Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

Katz H, Wassie E, Alsharedi M.

Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8. Review.

PMID:
28864844
3.

Atezolizumab in urothelial bladder carcinoma.

Hamilou Z, Lavaud P, Loriot Y.

Future Oncol. 2018 Feb;14(4):331-341. doi: 10.2217/fon-2017-0433. Epub 2017 Nov 14. Review.

PMID:
29135284
4.

Recent developments in the treatment of advanced bladder cancer.

Godwin JL, Hoffman-Censits J, Plimack E.

Urol Oncol. 2018 Mar;36(3):109-114. doi: 10.1016/j.urolonc.2017.12.018. Epub 2018 Feb 1. Review.

PMID:
29395952
5.

Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.

Tripathi A, Plimack ER.

Curr Urol Rep. 2018 Nov 7;19(12):109. doi: 10.1007/s11934-018-0851-7. Review.

PMID:
30406502
6.

First-line treatment of metastatic disease: cisplatin-ineligible patients.

Cathomas R, De Santis M, Galsky MD.

Hematol Oncol Clin North Am. 2015 Apr;29(2):329-40, x. doi: 10.1016/j.hoc.2014.10.006. Epub 2014 Dec 15. Review.

PMID:
25836938
7.

First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

Abida W, Bajorin DF, Rosenberg JE.

Hematol Oncol Clin North Am. 2015 Apr;29(2):319-28, ix-x. doi: 10.1016/j.hoc.2014.10.005. Epub 2014 Dec 15. Review.

PMID:
25836937
8.

Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.

Zibelman M, Ramamurthy C, Plimack ER.

Urol Oncol. 2016 Dec;34(12):538-547. doi: 10.1016/j.urolonc.2016.10.017. Review.

PMID:
27888981
9.

Recent advances in treatment of advanced urothelial carcinoma.

Kim JJ.

Curr Urol Rep. 2012 Apr;13(2):147-52. doi: 10.1007/s11934-012-0238-0. Review.

10.

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI.

Clin Adv Hematol Oncol. 2017 Jun;15(6):466-477. Review.

PMID:
28749907
11.

Atezolizumab in invasive and metastatic urothelial carcinoma.

Crist M, Balar A.

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1295-1301. doi: 10.1080/17512433.2017.1389275. Epub 2017 Oct 30. Review.

PMID:
28994323
12.

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A; Phase II study of Hellenic Co-operative Oncology Group.

Urology. 2004 Sep;64(3):479-84.

PMID:
15351574
13.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422
14.

Durvalumab in urothelial cancers.

Lavaud P, Hamilou Z, Loriot Y, Massard C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5. Review.

PMID:
29486607
15.

Pembrolizumab for the treatment of bladder cancer.

Sundahl N, Rottey S, De Maeseneer D, Ost P.

Expert Rev Anticancer Ther. 2018 Feb;18(2):107-114. doi: 10.1080/14737140.2018.1421461. Epub 2017 Dec 29. Review.

PMID:
29284318
16.

Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function.

Izumi K, Iwamoto H, Yaegashi H, Shigehara K, Nohara T, Kadono Y, Mizokami A.

In Vivo. 2019 Jan-Feb;33(1):167-172. doi: 10.21873/invivo.11454.

17.

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

Aoun F, Rassy EE, Assi T, Albisinni S, Katan J.

Immunotherapy. 2017 Mar;9(5):451-460. doi: 10.2217/imt-2017-0007. Review.

PMID:
28357911
18.

Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.

Gill DM, Sonpavde G, Pal SK, Agarwal N.

Immunotherapy. 2017 May;9(6):463-466. doi: 10.2217/imt-2017-0033. No abstract available.

19.

Current and future perspectives in advanced bladder cancer: is there a new standard?

von der Maase H.

Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14. Review.

PMID:
11894002
20.

Emerging drugs for urothelial carcinoma.

Gartrell BA, Sonpavde G.

Expert Opin Emerg Drugs. 2013 Dec;18(4):477-94. doi: 10.1517/14728214.2013.853741. Epub 2013 Nov 6. Review.

PMID:
24195728

Supplemental Content

Support Center